

The burden of rheumatoid arthritis and access to treatment

European Journal of Health Economics

8, 49-60

DOI: [10.1007/s10198-007-0088-8](https://doi.org/10.1007/s10198-007-0088-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current status of gene therapy for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2008, 10, 398-404.	4.7	5
2	The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life. <i>Open Access Rheumatology: Research and Reviews</i> , 2009, 1, 95.	1.6	3
3	History of health technology assessment in Hungary. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 120-126.	0.5	24
4	The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. <i>Rheumatology</i> , 2009, 48, 1283-1289.	1.9	58
5	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1592-1600.	6.7	78
7	Diagnosis and referral of rheumatoid arthritis by primary care physician: results of a pilot study on the city of Pisa, Italy. <i>Clinical Rheumatology</i> , 2010, 29, 71-81.	2.2	15
8	Future challenges for health economics and health technology assessment of biological drugs. <i>European Journal of Health Economics</i> , 2010, 11, 235-238.	2.8	6
9	Cost-effectiveness analysis for priority-setting in South Africa - what are the possibilities?. <i>South African Medical Journal</i> , 2010, 100, 816.	0.6	5
10	The significance of presenteeism for the value of lost production: the case of rheumatoid arthritis. <i>ClinicoEconomics and Outcomes Research</i> , 2010, 2, 105.	1.9	16
11	The Economic Burden of Rheumatoid Arthritis: Asia/Thailand Perspective. , 2010, , 1733-1750.		1
12	Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. <i>Rheumatology</i> , 2010, 49, 1920-1928.	1.9	47
13	Societal cost of rheumatoid arthritis patients in the US. <i>Current Medical Research and Opinion</i> , 2010, 26, 77-90.	1.9	191
14	The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 773-786.	3.1	12
15	The efficacy and safety of golimumab in the treatment of arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1131-1143.	3.1	3
16	Impatto sanitario e costi sociali dell'artrite reumatoide. <i>Giornale Italiano Di Health Technology Assessment</i> , 2010, 3, 81-87.	0.1	0
17	The Balancing Act of Autoimmunity: Central and Peripheral Tolerance Versus Infection Control. <i>International Reviews of Immunology</i> , 2010, 29, 211-233.	3.3	5
18	Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain. <i>Value in Health</i> , 2011, 14, 192-200.	0.3	24
19	Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (NI-28312141). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7860-7883.	6.4	30

#	ARTICLE	IF	CITATIONS
20	Artrite reumatoide: uma visão atual. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2011, 47, 495-503.	0.3	22
22	Kinematic Analysis of Gait Following Intra-articular Corticosteroid Injection into the Knee Joint with an Acute Exacerbation of Arthritis. <i>Physiotherapy Canada</i> <i>Physiotherapie Canada</i> , 2011, 63, 395-404.	0.6	4
23	Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. <i>British Journal of Pharmacology</i> , 2011, 162, 1470-1484.	5.4	25
24	Economic consequences and potential benefits. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 607-624.	3.3	45
25	The economic burden of rheumatoid arthritis: beyond health care costs. <i>Clinical Rheumatology</i> , 2011, 30, 25-32.	2.2	48
26	Willingness to pay for improvement of physical function among rheumatoid arthritis patients as measured by Health Assessment Questionnaire. <i>Rheumatology International</i> , 2011, 31, 347-352.	3.0	9
27	A transmissive laser speckle imaging technique for measuring deep tissue blood flow: An example application in finger joints. <i>Lasers in Surgery and Medicine</i> , 2011, 43, 21-28.	2.1	22
28	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review. <i>Arthritis Care and Research</i> , 2011, 63, 65-78.	3.4	73
29	How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis?. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 12-16.	1.1	11
30	The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990-2010: before and after introduction of biologic agents. <i>Rheumatology</i> , 2012, 51, 338-346.	1.9	44
31	The role of tocilizumab monotherapy in the management of rheumatoid arthritis: a review. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 9-19.	0.3	3
32	Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. <i>Reumatologia Clínica</i> , 2012, 8, 168-173.	0.5	47
33	The State of Health Economic Research in South Africa. <i>Pharmacoeconomics</i> , 2012, 30, 925-940.	3.3	26
34	Taking advances from bench to bedside during the last decade. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 225-236.	3.3	5
35	The need to address the burden of musculoskeletal conditions. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 183-224.	3.3	235
36	An intervention program with the aim to improve and maintain work productivity for workers with rheumatoid arthritis: design of a randomized controlled trial and cost-effectiveness study. <i>BMC Public Health</i> , 2012, 12, 496.	2.9	9
37	Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. <i>Reumatologia Clínica (English Edition)</i> , 2012, 8, 168-173.	0.3	27
38	Development of a Composite Questionnaire, the Valuation of Lost Productivity, to Value Productivity Losses: Application in Rheumatoid Arthritis. <i>Value in Health</i> , 2012, 15, 46-54.	0.3	54

#	ARTICLE	IF	CITATIONS
39	Cost of Illness and Quality of Life of Patients with Rheumatoid Arthritis in South Korea. Value in Health, 2012, 15, S43-S49.	0.3	19
40	Medical costs for Korean patients with rheumatoid arthritis based on the national claims database. Rheumatology International, 2012, 32, 2893-2899.	3.0	9
41	Biologic Rheumatoid Arthritis Therapies. BioDrugs, 2012, 26, 65-70.	4.6	10
42	The Development of Targeted Drug Delivery Systems for Rheumatoid Arthritis Treatment. , 0, , .		0
43	Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients. Rheumatology International, 2012, 32, 921-926.	3.0	3
44	Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. Health Economics Review, 2013, 3, 5.	2.0	11
45	Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database. Rheumatology International, 2013, 33, 2577-2584.	3.0	13
46	Current therapies in rheumatoid arthritis: A Latin American perspective. ReumatologÃa ClÃnica, 2013, 9, 106-112.	0.5	50
47	Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). European Journal of Internal Medicine, 2013, 24, 597-603.	2.2	93
48	â€œThey just scraped off the callusesâ€: a mixed methods exploration of foot care access and provision for people with rheumatoid arthritis in southâ€western Sydney, Australia. Journal of Foot and Ankle Research, 2013, 6, 34.	1.9	25
49	SectionÃ3: Rheumatoid Arthritis. Clinical Drug Investigation, 2013, 33, 113-132.	2.2	1
50	Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis. Joint Bone Spine, 2013, 80, 608-612.	1.6	19
51	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. Journal of Rheumatology, 2013, 40, 768-780.	2.0	108
52	PrÃ©valence des comorbiditÃ©s chez les patients atteints dâ€™une polyarthrite rhumatoÃ¯de suivis en consultation. Revue Du Rhumatisme (Edition Francaise), 2013, 80, 467-472.	0.0	2
53	Current therapies in rheumatoid arthritis: A Latin American perspective. ReumatologÃa ClÃnica (English) Tj ETQq0 0,0 rgBT /Qverlock 10	0.3	2
54	Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?. Clinical Rheumatology, 2013, 32, 151-159.	2.2	28
55	Induction of response with etanerceptâ€“methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clinical Rheumatology, 2013, 32, 1275-1281.	2.2	15
56	Prospects of Gene Therapy. , 2013, , 133-150.		1

#	ARTICLE	IF	CITATIONS
57	Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 555.	1.9	8
58	The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise. <i>Reumatismo</i> , 2014, 65, 271.	0.9	8
59	Biomarkers Predicting a Need for Intensive Treatment in Patients with Early Arthritis. <i>Current Pharmaceutical Design</i> , 2014, 21, 170-181.	1.9	22
60	Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 9-18.	1.4	1
61	Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 35-43.	2.8	33
62	Estimating the health-care usage associated with osteoarthritis and rheumatoid arthritis in an older adult population in Ireland. <i>Journal of Public Health</i> , 2014, 36, 504-510.	1.8	11
63	Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden. <i>Rheumatology</i> , 2014, 53, 153-160.	1.9	35
64	Canadian Estimates of Health Care Utilization Costs for Rheumatoid Arthritis Patients With and Without Therapy With Biologic Agents. <i>Arthritis Care and Research</i> , 2014, 66, 1319-1327.	3.4	27
65	Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis. <i>Rheumatology International</i> , 2014, 34, 1751-1758.	3.0	22
66	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014, 16, R56.	3.5	108
67	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
68	The Burden of Disease in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2014, 32, 841-851.	3.3	129
69	Anti-inflammatory and antioxidant activities of <i>Costus afer</i> Ker Gawl. hexane leaf fraction in arthritic rat models. <i>Journal of Ethnopharmacology</i> , 2014, 155, 543-551.	4.1	27
70	Footwear Experiences of People With Chronic Musculoskeletal Diseases. <i>Arthritis Care and Research</i> , 2015, 67, 1164-1172.	3.4	8
71	The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0119683.	2.5	75
72	Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries. <i>Rheumatology International</i> , 2015, 35, 1791-1797.	3.0	8
73	Near Infrared Fluorescence Imaging for early detection, monitoring and improved intervention of diseases involving the joint. <i>Connective Tissue Research</i> , 2015, 56, 153-160.	2.3	17
74	Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 648-654.	0.9	38

#	ARTICLE	IF	CITATIONS
75	A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. <i>Rheumatology International</i> , 2015, 35, 1837-1849.	3.0	20
76	Economic impact of musculoskeletal disorders (MSDs) on work in Europe. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 356-373.	3.3	404
77	The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. <i>Advances in Therapy</i> , 2015, 32, 742-756.	2.9	127
78	Productivity at work and quality of life in patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 107.	1.9	61
79	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	3.0	83
80	Economic Analytical Methods for Work-related MSD Cost Prediction. <i>Procedia Manufacturing</i> , 2015, 3, 4181-4188.	1.9	6
82	Longterm Work Productivity Costs Due to Absenteeism and Permanent Work Disability in Patients with Early Rheumatoid Arthritis: A Nationwide Register Study of 7831 Patients. <i>Journal of Rheumatology</i> , 2016, 43, 2101-2105.	2.0	14
83	Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. <i>Clinical Therapeutics</i> , 2016, 38, 1359-1375.e1.	2.5	19
84	Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. <i>Rheumatology</i> , 2016, 55, 1803-1811.	1.9	23
85	Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden. <i>Journal of Rheumatology</i> , 2016, 43, 1292-1299.	2.0	17
86	Process Evaluation of a Workplace Integrated Care Intervention for Workers with Rheumatoid Arthritis. <i>Journal of Occupational Rehabilitation</i> , 2016, 26, 382-391.	2.2	3
87	Psychological predictors of pain severity, pain interference, depression, and anxiety in rheumatoid arthritis patients with chronic pain. <i>British Journal of Health Psychology</i> , 2016, 21, 336-350.	3.5	44
88	A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. <i>Rheumatology International</i> , 2016, 36, 685-695.	3.0	201
89	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 231-241.	3.0	10
90	Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients. <i>Clinical Drug Investigation</i> , 2017, 37, 375-386.	2.2	14
91	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
92	Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. <i>Rheumatology International</i> , 2017, 37, 1111-1123.	3.0	10
93	Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. <i>Journal of Medical Economics</i> , 2017, 20, 703-714.	2.1	15

#	ARTICLE	IF	CITATIONS
94	â€œOfficial Viewâ€ on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. <i>Arthritis Care and Research</i> , 2017, 69, 1134-1141.	3.4	39
95	Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10Âyears apart. <i>Clinical Rheumatology</i> , 2017, 36, 499-506.	2.2	9
97	Economic evaluation of an intervention program with the aim to improve atâ€work productivity for workers with rheumatoid arthritis. <i>Journal of Occupational Health</i> , 2017, 59, 267-279.	2.1	12
98	The Economic Utility of Clinical Psychology in the Multidisciplinary Management of Pain. <i>Frontiers in Psychology</i> , 2017, 8, 1860.	2.1	4
99	One-year Predictors of Presenteeism in Workers with Rheumatoid Arthritis: Disease-related Factors and Characteristics of General Health and Work. <i>Journal of Rheumatology</i> , 2018, 45, 766-770.	2.0	17
100	Impact of a fatigue management in work programme on meeting work demands of individuals with rheumatic diseases: A pilot study. <i>Musculoskeletal Care</i> , 2018, 16, 398-404.	1.4	10
101	Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: realâ€world evidence using a nationwide database. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1227-1236.	1.9	10
102	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	30.5	1,441
103	Quality of life and functional capacity in patients with rheumatoid arthritis â€ Cross-sectional study. <i>ReumatologÃa ClÃnica</i> , 2018, 14, 360-366.	0.5	26
104	Analisi di budget impact del biosimilare di etanercept: lo scenario italiano. <i>Global &amp; Regional Health Technology Assessment</i> , 2018, 2018, 228424031876680.	0.1	3
105	Quality of life and functional capacity in patients with rheumatoid arthritis â€ Cross-sectional study. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2018, 14, 360-366.	0.3	3
106	Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1070.	3.5	30
108	Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector. <i>Value in Health Regional Issues</i> , 2018, 16, 99-105.	1.2	0
109	Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland. <i>Advances in Therapy</i> , 2018, 35, 1426-1437.	2.9	6
110	Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 57.	4.7	53
111	Absence of Pharmacokinetic Interactions between the Brutonâ€™s Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 202-207.	2.5	4
112	Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatmentâ€ A Systematic Literature Review. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2966.	2.6	14
113	Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada. <i>Rheumatology International</i> , 2019, 39, 1621-1630.	3.0	5

#	ARTICLE	IF	CITATIONS
114	Detection of Increased Relative Expression Units of Bacteroides and Prevotella, and Decreased Clostridium leptum in Stool Samples from Brazilian Rheumatoid Arthritis Patients: A Pilot Study. Microorganisms, 2019, 7, 413.	3.6	32
115	<p>Achieving comprehensive remission or low disease activity in rheumatoid patients and its impact on workability &ndash; Saudi Rheumatoid Arthritis Registry</p>. Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 89-95.	1.6	4
116	Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis. Advances in Therapy, 2019, 36, 2086-2095.	2.9	11
117	Mindfulness-Based Stress Reduction with Individuals Who Have Rheumatoid Arthritis: Evaluating Depression and Anxiety as Mediators of Change in Disease Activity. Mindfulness, 2019, 10, 1328-1338.	2.8	5
118	Therapeutic effect of Parmotrema tinctorum against complete Freundâ€™s adjuvant-induced arthritis in rats and identification of novel Isophthalic ester derivative. Biomedicine and Pharmacotherapy, 2019, 112, 108646.	5.6	18
119	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology, 2019, 10, 279.	3.5	89
120	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. Pharmacoeconomics, 2019, 37, 829-843.	3.3	16
121	Improvements in productivity and increased participation in daily activities over 52Âweeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study. Acta Clinica Belgica, 2019, 74, 342-350.	1.2	3
122	Association learning of Chinese herbal medicines and disease treatment efficacy. International Journal of Production Research, 2019, 57, 683-702.	7.5	2
123	Living With Rheumatoid Arthritis in Spain: A Qualitative Study of Patient Experience and the Role of Health Professionals. Clinical Nursing Research, 2020, 29, 551-560.	1.6	7
124	Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS ONE, 2020, 15, e0226754.	2.5	8
125	Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-Î± Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 8146-8156.	6.4	20
126	The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. Rheumatology Advances in Practice, 2020, 4, rkaa041.	0.7	10
127	The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1236-1242.	0.9	3
128	TRI microparticles prevent inflammatory arthritis in a collagen-induced arthritis model. PLoS ONE, 2020, 15, e0239396.	2.5	11
129	Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Research and Therapy, 2021, 23, 25.	3.5	30
130	High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?. Pharmacoeconomics - Open, 2021, 5, 385-396.	1.8	11
131	Coupling of Co-expression Network Analysis and Machine Learning Validation Unearthed Potential Key Genes Involved in Rheumatoid Arthritis. Frontiers in Genetics, 2021, 12, 604714.	2.3	9



#	ARTICLE	IF	CITATIONS
133	Efficacy and safety of Guizhi-Shaoyao-Zhimu decoction in the treatment of rheumatoid arthritis. <i>Medicine (United States)</i> , 2021, 100, e24416.	1.0	2
134	Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 638444.	4.8	19
135	Knowledge of disease, diagnosis, adherence and impact of research in an Irish cohort of patients with inflammatory arthritis. <i>HRB Open Research</i> , 0, 4, 60.	0.6	0
137	Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort. <i>PLoS ONE</i> , 2014, 9, e97077.	2.5	19
138	EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. <i>PLoS ONE</i> , 2017, 12, e0169946.	2.5	25
140	The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-222.	2.8	43
141	Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. <i>Health Technology Assessment</i> , 2019, 23, 1-130.	2.8	18
142	A Budget impact analysis of adalimumab biosimilar: the Italian context. <i>AboutOpen</i> , 2019, 6, 16-23.	0.2	3
144	Socioeconomic and Employment Status of Patients with Rheumatoid Arthritis in Korea. <i>Epidemiology and Health</i> , 2012, 34, e2012003.	1.9	14
145	An updated overview of immune complex mediated rheumatoid arthritis. <i>International Journal of Research in Medical Sciences</i> , 2014, 2, 398.	0.1	3
146	Economic Considerations in the Treatment of Rheumatic Diseases. , 2010, , 440-450.		0
148	The Importance of the Biopsychosocial Model for Understanding the Adjustment to Arthritis. , 2016, , 3-20.		4
149	Use of Rheumatologic Testing in Patients Who Eventually Receive a Diagnosis of Rheumatoid Arthritis. <i>Southern Medical Journal</i> , 2019, 112, 535-538.	0.7	1
150	Deep Breathing Increases Heart Rate Variability in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 261-266.	0.9	5
151	Cost-Effectiveness Analysis of Etanercept 25 mg Maintenance Therapy After Treatment with Etanercept 50 mg for Moderate Rheumatoid Arthritis in the PRESERVE Trial in Japan. <i>Value in Health Regional Issues</i> , 2022, 28, 105-111.	1.2	2
152	Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, , 1-8.	1.4	0
156	Assessment of depression, anxiety, stress, and quality of life in rheumatoid arthritis patients and comparison with healthy individuals. <i>Industrial Psychiatry</i> , 2021, 30, 195.	0.8	5
157	Randomised controlled trial of cognitive behaviour therapy versus mindfulness for people with rheumatoid arthritis with and without a history of recurrent depression: study protocol and design. <i>BMJ Open</i> , 2022, 12, e056504.	1.9	3

#	ARTICLE	IF	CITATIONS
158	Immune-Mediated Diseases from the Point of View of Psychoneuroimmunoendocrinology. <i>Biology</i> , 2022, 11, 973.	2.8	8
159	Experience with Adalimumab Biosimilar in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis at our District General Hospital in Shropshire, United Kingdom. , 0, 32, 135-137.		0
160	Modulating Heart Rate Variability through Deep Breathing Exercises and Transcutaneous Auricular Vagus Nerve Stimulation: A Study in Healthy Participants and in Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus. <i>Sensors</i> , 2022, 22, 7884.	3.8	4
161	Validation of traditional claims of anti-arthritic efficacy of trans-Himalayan snow mountain garlic ( <i>Allium ampeloprasum</i> L.) extract using adjuvant-induced arthritis rat model: A comparative evaluation with normal garlic ( <i>Allium sativum</i> L.) and dexamethasone. <i>Journal of Ethnopharmacology</i> , 2023, 303, 115939.	4.1	1
162	Investigating associations between access to rheumatology care, treatment, continuous care and healthcare utilization and costs among older individuals with RA. <i>Journal of Rheumatology</i> , 0, , jrheum.220729.	2.0	0
163	Projecting direct medical costs and productivity benefits of improving access to advanced therapy for rheumatoid arthritis: a projection modelling study. <i>Journal of Market Access &amp; Health Policy</i> , 2023, 11, .	1.5	0
165	New Generation smart drug delivery systems for Rheumatoid arthritis. <i>Current Pharmaceutical Design</i> , 2023, 29, .	1.9	0
166	Knowledge of disease, diagnosis, adherence and impact of research in an Irish cohort of patients with inflammatory arthritis. <i>HRB Open Research</i> , 0, 4, 60.	0.6	0
167	Evaluation des Nutzens. , 2023, , 37-179.		0
168	Household catastrophic health expenditures for rheumatoid arthritis: a single centre study from South India. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
169	The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment. <i>Value in Health Regional Issues</i> , 2024, 40, 13-18.	1.2	0
170	Double positivity for rheumatoid factor and anti-CCP autoantibodies: improving referral from primary care of patients suspected of having rheumatoid arthritis. <i>Primary Health Care Research and Development</i> , 2024, 25, .	1.2	0
171	Association of Mediterranean diet pattern with disease activity in the patients with rheumatoid arthritis: A cross-sectional study on Iranian patients. <i>Clinical Nutrition ESPEN</i> , 2024, 60, 95-101.	1.2	0